Fake press release on drug pricing “erroneously attributed” to Pfizer

pharmafile | April 1, 2016 | News story | Medical Communications Pfizer, fake, false, legal action, press release, washington post 

Pfizer (NYSE: PFE) has issued a statement on a false press release related to drug pricing that was reported on by the Washington Post.

The Washington Post quickly took down the story but left an explanation as to the process involved in its original publication. They indicate that the press release was circulated from what appeared to a real Pfizer spokesperson. The domain of the web address, which has since been taken then, was a fake website that closely mirrored the real Pfizer website. A reporter from the Post called the phone number at the bottom of the press released and left a voicemail.

The genuine Pfizer statement reads: “A false press release related to drug pricing and linking to a fake web site was anonymously issued earlier today. It was erroneously attributed to Pfizer and should be disregarded. Pfizer is investigating this matter and evaluating its legal options against the parties responsible. Pfizer is committed to engaging in a honest discussion and real dialogue about the issues that matter to patients.”

Sean Murray

Related Content

CDC Advisory Committee recommends Pfizer’s RSV vaccine

Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …

FDA approves Pfizer’s vaccine for the prevention of RSV in children

On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo …

Latest content